Type 2 Diabetes News and Research RSS Feed - Type 2 Diabetes News and Research

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.
TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure. [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]
Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

It’s been over a decade since the first Diabetes Attitudes Wishes and Needs (DAWN) study showed that psychosocial aspects of diabetes pose specific challenges and barriers to optimal glycaemic control for people living with diabetes. [More]
Researchers reveal why Peel has one of highest rates of diabetes in Ontario

Researchers reveal why Peel has one of highest rates of diabetes in Ontario

According to researchers at St. Michael's Hospital, there are two significant reasons why Peel has one of the highest rates of diabetes in Ontario: neighbourhood design that discourages walking and a population with many residents whose ethnic backgrounds predispose them to diabetes. [More]

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD). [More]

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

​In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases. [More]

Researcher analyses effect of chromium supplementation on blood sugar

Approximately 26 percent of the U.S. population has impaired fasting glucose, which is a predisposition for developing type 2 diabetes, and chromium supplementation has been suggested as a method that may help control and prevent the disease. [More]
Childhood obesity rates stabilize in recent years, study finds

Childhood obesity rates stabilize in recent years, study finds

Childhood obesity rates leveled off during a 14-year period between 1999 and 2012, according to research published Monday in the Journal of the American Medical Association: Pediatrics. But the rate of severe obesity increased, especially in Hispanic girls and black boys, according to the study. [More]

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. [More]

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society. [More]
TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. [More]

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects. [More]

GI Dynamics establishes reimbursement coverage for EndoBarrier Therapy for treatment of type 2 diabetes, obesity

GI Dynamics, Inc. today announced that Clalit Health Services, Israel's largest and one of the world's largest health maintenance organization, has established a reimbursement coverage policy for EndoBarrier Therapy, an endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. [More]

Adolescents in Sweden are at increased risk for type 1 diabetes than previously thought

New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) suggests that Sweden-the country already thought to have the second highest prevalence of type 1 diabetes in the world-could have 2-3 times more adolescents and young adults with type 1 diabetes than previously estimated. [More]
Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States. [More]

Lifestyle interventions may help pre-diabetics dodge risk of death from cardiovascular disease

Many research studies have shown that lifestyle interventions, such as exercise programmes or weight loss, in people with impaired glucose tolerance (those at high risk of diabetes) can prevent progression to overt type 2 diabetes. However, until now, there has been a lack of high quality, randomized controlled trial evidence to prove that lifestyle interventions prevent deaths from cardiovascular disease, such as heart attacks and stroke, in these people. [More]

Metabolon announces launch of fourth-generation metabolomics platform

Metabolon, Inc., a leader in metabolomics-driven biomarker discovery, announced today the launch of DiscoveryHD4, the company's fourth-generation metabolomics platform. [More]
Study of diabetes prevention programmes suggests need for more implementation of NICE guidance

Study of diabetes prevention programmes suggests need for more implementation of NICE guidance

University of Leicester study of diabetes prevention programmes suggests need for more rigorous implementation of NICE guidance [More]

Oats Nutrition and Technology: A comprehensive textbook from Quaker

Considered the most comprehensive and up-to-date textbook about the life cycle of oats, Oats Nutrition and Technology was released from Wiley-Blackwell publishers, and is now available at all major online publishing websites, including Amazon.com. [More]